Navigation Links
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Date:12/2/2009

Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About KRX-0401 (Perifosine)

KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, with evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the American Cancer Society, in 2009 there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,500 deaths from multiple myeloma in the United States. To date, several FDA approved therapies exist for the treatment of multiple myeloma. Despite this progress, patients continue to relapse, become refractory to prior treatments and eventually die from their disease. Thus, new therapies are needed to treat these patients and extend their survival.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically importa
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
2. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
7. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
8. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... For the pharmaceutical industry, marketplace success is tied to ... importance of the managed markets function - which is pharma,s ... payer formularies and provider networks play an increasingly large role ... time, managed markets leaders must continually identify the optimal resource ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... NORCROSS, Ga., Feb. 24, 2012   Molnlycke Health Care US, LLC, ... announces it has acquired the assets of Brennen Medical (St. ... Care. In this transaction (terms not disclosed), ... Assets of Brennen Medical within the Burn and Wound Care ...
...  Mylan Inc. (Nasdaq: MYL ) today announced ... the company,s Mylan Pharmaceuticals subsidiary, has been elected to ... board of directors. GPhA is an association that represents ... election to this role further supports Mylan,s mission to ...
Cached Medicine Technology:Molnlycke Health Care Acquires the Burn and Wound Care Business From Brennen Medical 2Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA 2
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... and Discuss Emerging Advances in Basic Research ... Symposium, ABBOTT PARK, Ill., Nov. 1 The ... use to,communicate to one another, in order to maintain ... Based on a growing body of,scientific knowledge related to ...
... Capsugel will,unveil the successor to its unique Xcelodose ... vials at the American Association of,Pharmaceutical Scientists (AAPS) ... The new Xcelodose S system will feature ... Additional improvements include an integral High,Throughput Unit and ...
... a leading global clinical,research organization is delighted to announce that ... Trials Conference; which will be held,November 5th to 8th, 2007 ... sponsor "welcome coffee breaks" from 7:00 to,8:20 am on Nov. ... Chiltern will,also be present at exhibit booth 66. "We ...
... Confessions/ Testimonials for ... and LONDON, Nov. 1 Thomson,Scientific, part of ... TOC) and,leading provider of information solutions to the ... of its new campaign,"Confessions ... of a User." ...
... Oct. 31 All-State Properties, L.P.,announced today the ... Technology Co., Ltd. which contemplated a reverse,merger with ... terms of the Acquisition Agreement, Hubei Longdan is,obligated ... the transaction,as well as expenses relating to maintenance ...
... MIAMI, Oct. 31 Pensacola, FL-based Cogon Systems, ... (HIE) for South,Florida known as the South Florida ... participating providers who undergo a,short training session will ... search for,patient data from multiple healthcare organizations. ...
Cached Medicine News:Health News:Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition 2Health News:Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition 3Health News:Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition 4Health News:Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition 5Health News:New Generation Xcelodose(R)S Precision Drug Powder Micro-filling System Offers 50% Increased Throughput 2Health News:Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam 2Health News:Thomson Scientific Launches 'Confessions ... of a User' Campaign Asking 'Are You the New Face of Research?' 2Health News:South Florida HIE Phase II Completed and Phase III Awarded 2
... OTI-Scan 3D is the ... system available today. This ... and A-scan system operates ... desktop or laptop computer ...
... is a portable, digital A-scan system which ... of a high frequency, low noise probe ... immediately upon application of the probe along ... live A-scan display, storage of 5 different ...
... Echoscan US-800 Ultrasonic A-Scan offers ... compact, portable package. Besides,its compact ... highly accurate measurement and easy ... automatic freezing and manual gate.,NIDEK ...
... first very high frequency digital ultrasound eye ... provides microscopic resolution images and precision measurement ... of the human eye. Artemis is a ... In use, the patient leans forward placing ...
Medicine Products: